Summary of findings table ‐ Rifaximin vs placebo or no intervention
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
- Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2023 · Cochrane Headline outcomes onlyRR 1.05 [0.83, 1.32]9 studies · 801 participantsModerate